1. Home
  2. BFST vs PCRX Comparison

BFST vs PCRX Comparison

Compare BFST & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Business First Bancshares Inc.

BFST

Business First Bancshares Inc.

N/A

Current Price

$27.85

Market Cap

877.1M

Sector

Finance

ML Signal

N/A

Logo Pacira BioSciences Inc.

PCRX

Pacira BioSciences Inc.

N/A

Current Price

$23.05

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BFST
PCRX
Founded
2006
2006
Country
United States
United States
Employees
842
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
877.1M
1.0B
IPO Year
2014
2010

Fundamental Metrics

Financial Performance
Metric
BFST
PCRX
Price
$27.85
$23.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$32.75
$30.25
AVG Volume (30 Days)
142.3K
512.0K
Earning Date
04-27-2026
04-30-2026
Dividend Yield
2.23%
N/A
EPS Growth
23.45
107.44
EPS
0.68
0.07
Revenue
$10,704,000.00
$541,533,000.00
Revenue This Year
$22.71
$6.78
Revenue Next Year
$5.02
$8.54
P/E Ratio
$40.96
$329.14
Revenue Growth
1.20
26.04
52 Week Low
$22.56
$18.80
52 Week High
$30.32
$27.64

Technical Indicators

Market Signals
Indicator
BFST
PCRX
Relative Strength Index (RSI) 51.28 42.19
Support Level $26.78 $22.13
Resistance Level $27.89 $24.20
Average True Range (ATR) 0.49 1.01
MACD 0.03 -0.18
Stochastic Oscillator 74.42 16.85

Price Performance

Historical Comparison
BFST
PCRX

About BFST Business First Bancshares Inc.

Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Share on Social Networks: